Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events

BACKGROUND: In recent years, the BRAF-inhibitor vemurafenib has been successfully established in the therapy of advanced melanoma. Despite its superior efficacy, the use of vemurafenib is limited by frequent inflammatory cutaneous adverse events that affect patients’ quality of life and may lead to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy
Main Authors: Hawerkamp, Heike C., Kislat, Andreas, Gerber, Peter A., Pollet, Marius, Rolfes, Katharina M., Soshilov, Anatoly A., Denison, Michael S., Momin, Afaque A., Arold, Stefan T., Datsi, Angeliki, Braun, Stephan A., Oláh, Péter, Lacouture, Mario E., Krutmann, Jean, Haarmann-Stemmann, Thomas, Homey, Bernhard, Meller, Stephan
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6911016/
https://ncbi.nlm.nih.gov/pubmed/31269229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13972
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados